Shanghai Fosun Pharmaceutical has announced that its subsidiary, Zhejiang Xinghao Pengbo Pharmaceutical, has launched a Phase II clinical trial in China for XH-S003, a small molec ...
Children with AAV and kidney disease face increased risks for long-term renal damage at 1 year, despite the majority achieving inactive renal disease by this time.
Empagliflozin led to promising weight loss outcomes in patients with prediabetes and diabetes, with the results being more prominent in men than in women.